Sitagliptin for the Prevention and Treatment of Hyperglycemia in Patients With Type 2 Diabetes Undergoing Cardiac Surgery
Phase of Trial: Phase IV
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Sitagliptin (Primary) ; Insulin; Insulin aspart; Insulin glargine; Insulin lispro
- Indications Hyperglycaemia; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SITA-CABGDM
- 01 Dec 2017 Planned End Date changed from 1 Feb 2018 to 1 Mar 2019.
- 01 Dec 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 25 Jan 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.